WO2006102072A3 - Use of a pa131 polypeptide in treatment of atherosclerosis - Google Patents

Use of a pa131 polypeptide in treatment of atherosclerosis Download PDF

Info

Publication number
WO2006102072A3
WO2006102072A3 PCT/US2006/009699 US2006009699W WO2006102072A3 WO 2006102072 A3 WO2006102072 A3 WO 2006102072A3 US 2006009699 W US2006009699 W US 2006009699W WO 2006102072 A3 WO2006102072 A3 WO 2006102072A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
polypeptide
treatment
polypeptides
pal
Prior art date
Application number
PCT/US2006/009699
Other languages
French (fr)
Other versions
WO2006102072A2 (en
Inventor
Corinna Lebherz
John R White
James M Wilson
Original Assignee
Univ Pennsylvania
Smithkline Beecham Corp Dba Gl
Corinna Lebherz
John R White
James M Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Smithkline Beecham Corp Dba Gl, Corinna Lebherz, John R White, James M Wilson filed Critical Univ Pennsylvania
Publication of WO2006102072A2 publication Critical patent/WO2006102072A2/en
Publication of WO2006102072A3 publication Critical patent/WO2006102072A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of a PAl 31 polypeptide for treatment of atherosclerosis is described. PA131 polypeptides useful in the described regimens and compositions include human and murine PA131 polypeptides.
PCT/US2006/009699 2005-03-23 2006-03-17 Use of a pa131 polypeptide in treatment of atherosclerosis WO2006102072A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66436605P 2005-03-23 2005-03-23
US60/664,366 2005-03-23

Publications (2)

Publication Number Publication Date
WO2006102072A2 WO2006102072A2 (en) 2006-09-28
WO2006102072A3 true WO2006102072A3 (en) 2006-11-23

Family

ID=36859942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009699 WO2006102072A2 (en) 2005-03-23 2006-03-17 Use of a pa131 polypeptide in treatment of atherosclerosis

Country Status (1)

Country Link
WO (1) WO2006102072A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
ES2878451T3 (en) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Modulating polynucleotides
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
RU2762257C2 (en) 2016-04-15 2021-12-17 Зе Трастис Оф Зе Юниверсити Оф Пенсильвания Gene therapy for the treatment of hemophilia a
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
MX2018014152A (en) 2016-05-18 2019-03-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease.
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
JP7229989B2 (en) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド Trajectory array guide system
TWI722310B (en) 2017-08-03 2021-03-21 美商航海家醫療公司 Compositions and methods for delivery of aav
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2024505257A (en) 2021-02-01 2024-02-05 レジェンクスバイオ インコーポレーテッド Gene therapy for neuronal ceroid lipofuscinosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038602A2 (en) * 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
EP1500663A1 (en) * 2000-09-28 2005-01-26 Eli Lilly And Company Secreted proteins and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500663A1 (en) * 2000-09-28 2005-01-26 Eli Lilly And Company Secreted proteins and their uses
WO2002038602A2 (en) * 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEBHERZ CORINNA ET AL: "Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia.", June 2004, THE JOURNAL OF GENE MEDICINE. JUN 2004, VOL. 6, NR. 6, PAGE(S) 663 - 672, ISSN: 1099-498X, XP002396575 *

Also Published As

Publication number Publication date
WO2006102072A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006102072A3 (en) Use of a pa131 polypeptide in treatment of atherosclerosis
ZA200502618B (en) Human papillomavirus polypeptides and immunogenic compositions
HK1110508A1 (en) Compositions and methods of their use for improving the condition and appearance of skin
AU2003276822A8 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
EP1578437A4 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
AU2003303513A8 (en) Tissue reactive compounds and compositions and uses thereof
HK1094428A1 (en) Agent for eliminating singlet oxygen and composition using the same
AU2003249606A8 (en) Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
EP1871795A4 (en) Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2005074524A3 (en) Modified human interferon polypeptides and their uses
AU2002328343A1 (en) Wax-based compositions and the use thereof as body care agents
EP1570839A4 (en) Composition for preparation for external use on skin and method of using the same
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
HK1062567A1 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
EP1726008A4 (en) Bis-propylamine analog and composition
AU2003300780A1 (en) Rifalazil compositions and therapeutic regimens
EP1581243A4 (en) Oral lactoferrin in the treatment of sepsis
ZA200606216B (en) Modified human interferon polypeptides and their uses
WO2004032850A3 (en) Uses of human zven antagonists
PL1762219T3 (en) Photoprotective and/or photoimmunoprotective compositions for the skin and uses thereof
ZA200704017B (en) Scarecrow-like stress-related polypeptides and methods of use in plants
CA104272S (en) Video monitor
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
EP1959999A4 (en) Polynucleotides and polypeptide of human kv1.3, compositions comprising same and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06738727

Country of ref document: EP

Kind code of ref document: A2